Phase 4
N=40
Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Cytomegalovirus Disease
Bottom Line
View on ClinicalTrials.gov: NCT01509404 ↗Enrolled (actual)
40
Serious AEs
20.0%
Results posted
Oct 2018
Primary outcome: Primary: Number of Patients With Late CMV Disease — 0; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Valganciclovir (Drug); CMV hyperimmune globulin (Biological)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medical University of South Carolina
- Primary completion
- Dec 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Late CMV Disease |
0; 0 | — |
| SECONDARY Number of Patients With Early CMV Infection |
3; 1 | — |
| SECONDARY Number of Patients With Cell Mediated Immunity |
8; 13 | — |
| SECONDARY Renal Function |
57; 53; 59; 54; 59; 55 | — |
| SECONDARY Number of Participants With Acute Cellular and/or Antibody Mediated Rejection |
2; 6 | — |
| SECONDARY Number of Participants With Opportunistic Infections |
17; 19 | — |
| SECONDARY Number of Participants With Asymptomatic CMV Viremia |
1; 5 | — |
| SECONDARY Number of Participants With CMV Seroconversions |
13; 19 | — |
Summary
The purpose of the study is to assess the incidence and severity of late Cytomegalovirus (CMV) disease, defined as CMV syndrome or tissue invasive disease occurring between 100 and 200 days and after 200 days post-transplant in patients treated with valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant versus valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant.
Eligibility Criteria
Inclusion Criteria
- Male and female patients ≥ 18 years of age.
- Male or female patients who CMV seronegative receiving a kidney, pancreas or liver from a seropositive donor.
- Female patients of child bearing potential must have a negative urine or serum pregnancy test within the past 48 hours prior to receiving transplant or study inclusion.
- The patient has given written informed consent to participate in the study.
Exclusion Criteria
- Solid organ transplant recipient is CMV seropositive at the time of transplant.
- Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV).
- Patient has uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives.
- Patients with thrombocytopenia (<25, 000/mm3 ), with an absolute neutrophil count of < 1,000/mm3); and/or leucopoenia (< 2,000/mm3), or anemia (hemoglobin < 6 g/dL) prior to study inclusion.
- Patient is taking or has been taking an investigational drug in the 30 days prior to transplant.
- Patient has a known hypersensitivity to valganciclovir, tacrolimus, mycophenolate mofetil, rabbit anti-thymocyte globulin, CMV hyperimmune globulin, basiliximab or corticosteroids.
- Patients with severe diarrhea or other gastrointestinal disorders that might interfere with their ability to absorb oral medication.
- Patient is pregnant or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by positive human Chorionic Gonadotropin (hCG) laboratory test.
- Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator.
- Inability to cooperate or communicate with the investigator.
Data sourced from ClinicalTrials.gov (NCT01509404). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.